| Předmět: |
|
| Zdroj: |
Immunotherapy Weekly; 12/5/2023, p525-525, 1p |
| Abstrakt: |
A new report discusses research findings on squamous cell carcinoma, a type of cancer. The research focuses on the use of immune checkpoint inhibitors (ICIs) as a treatment for penile squamous cell carcinoma (pSCC). The study found that three patients who were ineligible for chemotherapy received immunotherapy with cemiplimab as a first-line treatment and achieved almost a complete response. This is the first real-world report of near complete response with cemiplimab in penile SCC. The research suggests that ICIs may be more effective than conventional chemotherapy for treating cancer. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
